The definitive benchmark for hematology dealmaking
Hematology partnering spans both malignant and non-malignant disorders, with deal structures reflecting the increasing use of targeted therapies, biologics, and advanced treatment modalities across the space.This report provides a comprehensive and structured analysis of 226 hematology collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.
Establish a clear view of market standards
The report enables a precise understanding of how hematology deals are structured in practice, allowing you to:
- Benchmark comparable transactions with confidence
- Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
- Define realistic market parameters
- Clear insight into how deal terms vary by stage, asset type, and partner profile
- Support valuation and structuring decisions with evidence
- Ground internal discussions in real transaction data rather than assumptions
- Understand how leading companies approach dealmaking
- Visibility into partner behaviour and recurring deal structures across a technically advanced and evolving therapeutic landscape
- Full visibility into deal structure and execution
This includes:
- Rights granted and retained
- Development and commercialization responsibilities
- Financial structures and payment triggers
- Key contractual provisions and protections
Designed for real-world BD and strategy use
The report is widely used to:
- Structure and benchmark live transactions
- Prepare for negotiations with well-defined market context
- Evaluate partnership opportunities and counterparties
- Support internal strategy with robust, defensible data
What’s included?
- 226 hematology collaboration and licensing deals
- Financial terms, including upfronts, milestones, and royalties where disclosed
- Fully searchable deal directory (by company, therapy, and technology)
- Direct access to SEC-filed agreements and source documents
- Analysis of deal trends, key transactions, and active dealmakers
- A trusted, evidence-based reference for hematology dealmaking
Table of Contents
Executive SummaryChapter 1 - Introduction
Chapter 2 - Trends in hematology dealmaking
Chapter 3 - Financial deal terms for hematology partnering
Chapter 4 - Leading hematology deals and dealmakers
Chapter 5 - Hematology contract document directory
Chapter 6 - Hematology dealmaking by therapeutic target
Deal directory
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2seventy bio
- 3DR Labs
- Abbvie
- ABVC BioPharma
- Acceleron Pharma
- Acrotech Biopharma
- Adaptive Biotechnologies
- AffaMed Therapeutics
- AgeX Therapeutics
- Agilent Technologies
- Agios Pharmaceuticals
- AkaRx
- Akebia Therapeutics
- Albert Einstein College of Medicine
- Alexion Pharmaceuticals
- Alfasigma
- Alivexis
- ALZpath
- Amag Pharmaceuticals
- American Red Cross
- American Society of Hematology
- Antengene
- Anthos Therapeutics
- Apellis Pharmaceuticals
- Aplagon
- Aplastic Anemia & MDS International Foundation
- Aptahem
- APT Therapeutics
- Arbor Biotechnologies
- ArcherDX
- Aruvant Sciences
- ASC Therapeutics
- ASKA Pharmaceuticals
- Association for the Advancement of Blood & Biotherapies
- AstraZeneca
- Atomwise
- Audaire Health
- Babson Diagnostics
- Baxalta
- Baxter International
- Bayer
- Bayer Healthcare
- Beam Therapeutics
- Becton Dickinson
- Beijing InnoCare Pharma
- Beth Israel Deaconess Medical Center
- Beyondspring Pharmaceuticals
- Bicycle Therapeutics
- Bill and Melinda Gates Foundation
- BillionToOne
- Bioceros
- BIOCORP
- Biolog-id
- BioMatrix Specialty Pharmacy
- Biomed Elements
- Biomedical Advanced Research and Development Authority
- BioNano Genomics
- BioSpring
- Bioverativ
- Blau Pharma
- Blood Centers of America
- Bluebird Bio
- Bluejay Diagnostics
- Boryung Pharmaceutical
- Bristol-Myers Squibb
- Brooklyn ImmunoTherapeutics
- C-Bridge Capital
- Cadila Pharmaceuticals
- Cadrenal Therapeutics
- California Institute for Regenerative Medicine
- Calithera Biosciences
- CAMP4 Therapeutics
- Canadian Blood Services
- Cardiovascular Systems
- Caring Cross
- Celgene
- Cellphire
- Cell Point
- Centogene
- Cerus
- Children's Hospital Boston
- Children's Hospital of Philadelphia
- Children's Hospital Of Wisconsin
- Children's Minnesota
- China Medical System
- Cincinnati Children’s Hospital Medical Center
- City of Hope
- Civica Rx
- CJ Corp
- Clinigen
- Codexis
- Comercializadora BioRenal
- Companhia Energetica Integrada
- ConcertAI
- CRISPR Therapeutics
- CSL Behring
- CSL Plasma
- Curetis
- CytoSorbents
- Daiichi Sankyo
- Danaher
- Daxor
- Defense Health Agency (US)
- Department of Defense
- Department of Health and Human Services
- Dialco Medical
- Diffusion Pharmaceuticals
- Disc Medicine
- Domainex
- Dong-A Pharmaceutical
- Drawbridge Health
- Drogsan Pharmaceuticals
- Duke University
- Eddingpharm
- Editas Medicine
- Eisai
- Emendo Biotherapeutics
- Enable Injections
- Enlaza Therapeutics
- Enzyre
- EpiDestiny
- Ergomed
- Esperion Therapeutics
- European Medicines Agency
- Evive Biotechnology
- Ewopharma
- ExCellThera
- Expression Therapeutics
- ExThera Medical
- Factor Bioscience
- Feinstein Institute for Medical Research
- Fibriant
- Fibrogen
- Foresee Pharmaceuticals
- Forty Seven
- Foundation for Innovative New Diagnostics
- Fresenius Medical Care
- Fulcrum Therapeutics
- GC Pharma
- GE Healthcare
- Genentech
- Genetix Biotherapeutics
- Genevant Sciences
- Genexine
- Genoptix
- GenScript ProBio
- GenVec
- German Federal Ministry of Education and Research
- Global Blood Therapeutics
- Golden Meditech
- Greiner Bio-One
- Grifols
- GSK
- HanAll Pharmaceuticals
- Handok Pharmaceuticals
- Healthcare Royalty Partners
- Hemanext
- Hemex Health
- HemoMinas Foundation
- Hemosonics
- HitGen
- Homology Medicines
- Hong Kong Red Cross Blood Transfusion Service
- Immunome
- Incyte
- Infomed
- Inmagene Biopharmaceuticals
- Innova Vascular
- Institute for Genome Statistics and Bioinformatics
- Institute of Hematology and Blood Transfusion
- Institute of Human Genetics
- Intas Pharmaceuticals
- Intellia Therapeutics
- inviCRO
- Ionis Pharmaceuticals
- Irish Haemophilia Society
- Jasper Therapeutics
- Jazz Pharmaceuticals
- JEIL Pharmaceutical
- Jiangsu Hansoh Pharmaceutical
- Jiangsu Hengrui Medicine
- Johnson & Johnson
- Kaleido Biosciences
- Kamada
- Kedrion Biopharma
- Keros Therapeutics
- Kiromic Biopharma
- Kissei Pharmaceutical
- Knight Therapeutics
- Kurin
- La Jolla Pharmaceutical
- LaNova Medicines
- Lee's Pharmaceutical
- LogicBio Therapeutics
- Loop Medical
- LUNAC Therapeutics
- MaaT Pharma
- Mabwell Bioscience
- Magenta Therapeutics
- Marathon Medical
- Massachusetts Institute of Technology
- Massive Bio
- Maxcyte
- Mayo Clinic
- MD Anderson Cancer Center
- Medical Technology Enterprise Consortium
- Medice Arzneimittel Pütter
- MedImmune
- Medison Pharma
- Melodia Therapeutics
- Menarini
- MicroHealth
- Minaris Regenerative Medicine
- MindRank AI
- Ministry of Defence
- Molecular Templates
- Nantes University
- National Cancer Institute
- National Center for Advancing Translational Sciences (NCATS)
- National Heart
- Lung and Blood Institute
- National Hemophilia Foundation
- National Institutes of Health
- NCPC GeneTech
- Nencki Institute
- Neogenomics
- Neoletix Biotechnology
- Neurimmune Therapeutics
- New York Blood Center
- Norgine
- Novartis
- Novellus Biopharma
- Novellus Therapeutics
- NovImmune
- Novo Nordisk
- Nxera Pharma
- Oak Hill Bio
- Omeros
- OMRF
- Onconova Therapeutics
- OncoX BioPharma
- Orchard Therapeutics
- Orna Therapeutics
- Otsuka
- Owkin
- Oxford BioMedica
- Pan American Cancer Treatment Centers
- PathoQuest
- PBM Capital Group
- Pfenex
- Pfizer
- PhaseBio Pharmaceuticals
- PicnicHealth
- Pieris Pharmaceuticals
- PixCell Medical
- Platelet BioGenesis
- Polifarma
- Portola Pharmaceuticals
- Poseida Therapeutics
- Precision BioSciences
- Pregene Biopharma
- Prime Therapeutics
- Prolytix
- Protagonist Therapeutics
- QIAGEN
- Queens University
- Quercis Pharma
- Regen BioPharma
- Regeneron Pharmaceuticals
- Regenesis Biomedical
- ReNAgade Therapeutics
- Resonance Health
- Rigel Pharmaceuticals
- Roche
- Rocket Pharmaceuticals
- Rockwell Medical
- Roivant Sciences
- Romanian National Institute of Infectious Diseases
- Royal College of Surgeons (Ireland)
- RPRD Diagnostics
- Sage Bionetworks
- Samsung Bioepis
- Sandoz
- Sangamo Therapeutics
- Sanguina
- Science Foundation Ireland
- Seattle Childrens Research Institute
- Selecta Biosciences
- Selexis
- SERB Pharmaceuticals
- Sernova
- Seventh Sense Biosystems
- SFJ Pharmaceuticals
- Shanghai RAAS Blood Products
- Shield Therapeutics
- Shionogi
- Shire Laboratories
- Shire Pharmaceuticals
- Sidero Bioscience
- Siemens Healthineers
- Sigilon Therapeutics
- Similis Bio
- Small Business Innovation Research
- SOPHiA Genetics
- Spark Therapeutics
- SQI Diagnostics
- SRS Life Sciences
- Statera Biopharma
- Strm.Bio
- Sumitomo Dainippon Pharma
- Supernus Pharmaceuticals
- Swedish Orphan Biovitrum
- Swiss Transfusion SRC
- Syna Therapeutics
- Syros Pharmaceuticals
- Sysmex
- Takeda Pharmaceutical
- Terumo Blood and Cell Technologies
- Teva Pharmaceutical Industries
- Therapeutic Solutions International
- Tivic Health Systems
- Trialbee
- TRPharm
- Turgut Ilaclari
- Uniformed Services University of the Health Sciences
- UniQure
- University Medical Center Utrecht
- University of Bonn
- University of Cincinnati
- University of Colorado
- University of Pittsburgh
- University of Texas
- US Army
- US Veterans Administration
- Velesco
- Velico Medical
- Veralox Therapeutics
- VeriSIM Life
- Versiti Blood Research Institute
- Vertex Pharmaceuticals
- Vifor Pharma
- Vigene Biosciences
- Vizient
- Wanbang Biopharmaceuticals
- Wanchunbulin
- Washington University in St Louis
- Werum IT Solutions
- Western New England University
- Xenetic Biosciences
- Zealand University Hospital
- Zenas BioPharma
- Zydus Cadila
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
